PrECOG
@precogonc.bsky.social
Innovative cancer research studies developed through industry partnerships and networks. Supporting ECOG-ACRIN's efforts to advance cancer care
Reposted by PrECOG
DYK funding for NIH and NCI ends on 1/30? Act now & ask Congress to support sustainable, long-term funding for biomedical & #CancerResearch for FY26: bit.ly/3LpZJau
Federal Funding for Cancer Research
As Congress negotiates Fiscal Year 2025 appropriations bills, urge them to make cancer research a top priority.
bit.ly
January 13, 2026 at 3:10 PM
DYK funding for NIH and NCI ends on 1/30? Act now & ask Congress to support sustainable, long-term funding for biomedical & #CancerResearch for FY26: bit.ly/3LpZJau
Kudos to Stanford Cancer Institute Palo Alto for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. bit.ly/pre1702-study
December 23, 2025 at 2:12 PM
Kudos to Stanford Cancer Institute Palo Alto for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. bit.ly/pre1702-study
Great work to Baptist Memorial Health Care for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. bit.ly/pre1702-study
December 17, 2025 at 2:49 PM
Great work to Baptist Memorial Health Care for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. bit.ly/pre1702-study
Tufts Medical Center is now enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. Learn more: bit.ly/pre1702-study
December 15, 2025 at 8:20 PM
Tufts Medical Center is now enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. Learn more: bit.ly/pre1702-study
Reposted by PrECOG
At #ASH2025, ECOG-ACRIN & @precogonc.bsky.social researchers will present data that could improve treatments for #AML, #ALL, #MCL, #CLL and more. View our full guide to the meeting: bit.ly/4rtkbHp #BloodCancer #leukemia #lymphoma
Guide to ASH 2025: ECOG-ACRIN and PrECOG are set to reveal multiple blood cancer research discoveries
Lear more about the 11 in-depth scientific analyses aim to enhance the precision and safety of treatments for hematologic malignancies.
bit.ly
December 4, 2025 at 9:09 PM
At #ASH2025, ECOG-ACRIN & @precogonc.bsky.social researchers will present data that could improve treatments for #AML, #ALL, #MCL, #CLL and more. View our full guide to the meeting: bit.ly/4rtkbHp #BloodCancer #leukemia #lymphoma
Geisinger Cancer Institute is now enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. Learn more: bit.ly/pre1702-study
December 3, 2025 at 2:21 PM
Geisinger Cancer Institute is now enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. Learn more: bit.ly/pre1702-study
Great work to Vanderbilt University Medical Center for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. bit.ly/pre1702-study
November 24, 2025 at 4:00 PM
Great work to Vanderbilt University Medical Center for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. bit.ly/pre1702-study
@stanford-cancer.bsky.social is now enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. Learn more: bit.ly/pre1702-study
November 24, 2025 at 3:54 PM
@stanford-cancer.bsky.social is now enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. Learn more: bit.ly/pre1702-study
In honor of #LungCancer Awareness Month, learn about PrE0510! This #ClinicalTrial is a phase II study of platinum/etoposide plus ivonescimab for extensive-stage small cell lung cancer (#SCLC). Click here for more 👉 bit.ly/49xgUR3 #LCAM #LCSM
November 24, 2025 at 3:49 PM
In honor of #LungCancer Awareness Month, learn about PrE0510! This #ClinicalTrial is a phase II study of platinum/etoposide plus ivonescimab for extensive-stage small cell lung cancer (#SCLC). Click here for more 👉 bit.ly/49xgUR3 #LCAM #LCSM
Reposted by PrECOG
On #WorldPancreaticCancerDay 💜 we are shining a light on two @eaonc.bsky.social clinical trials aiming to improve outcomes for patients with #PancreaticCancer & #PancreaticCysts - EA2185 and EA2192/APOLLO. Learn more here 👉 bit.ly/pancreaticf25
Ongoing Trials: A closer look at ECOG-ACRIN’s clinical trials for patients with pancreatic conditions
For Pancreatic Cancer Awareness Month, we highlight two actively recruiting clinical trials for patients with pancreatic conditions
bit.ly
November 20, 2025 at 4:51 PM
On #WorldPancreaticCancerDay 💜 we are shining a light on two @eaonc.bsky.social clinical trials aiming to improve outcomes for patients with #PancreaticCancer & #PancreaticCysts - EA2185 and EA2192/APOLLO. Learn more here 👉 bit.ly/pancreaticf25
Kudos to @virtuahealth.bsky.social for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. Learn more: bit.ly/pre1702-study
November 11, 2025 at 9:07 PM
Kudos to @virtuahealth.bsky.social for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. Learn more: bit.ly/pre1702-study
Reposted by PrECOG
The recently reported DREAM3R results show that, for pts w/ pleural #mesothelioma, the addition of durvalumab to chemo = higher tumor response—yet survival benefit is unclear. More research is needed. Read about this collab between @precogonc.bsky.social & @togaanz.bsky.social: bit.ly/47Pw02S
Durvalumab Plus Chemo Yields Inconclusive Results in Advanced Pleural Mesothelioma | OncLive
Durvalumab in combination with chemotherapy produced outcomes consistent with prior studies in patients with advanced pleural mesothelioma.
bit.ly
November 6, 2025 at 3:29 PM
The recently reported DREAM3R results show that, for pts w/ pleural #mesothelioma, the addition of durvalumab to chemo = higher tumor response—yet survival benefit is unclear. More research is needed. Read about this collab between @precogonc.bsky.social & @togaanz.bsky.social: bit.ly/47Pw02S
Great work to ProHealth Care for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. More: bit.ly/4hyZUue #LCSM
Spotlight on Real-World Data Capture: The PrE1702 Registry Study in Lung Cancer
This major new initiative is a unique opportunity for researchers and patients to help build an important real-world data registry of patients with EGFR-mutated non-small cell lung cancer
bit.ly
November 5, 2025 at 2:08 PM
Great work to ProHealth Care for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. More: bit.ly/4hyZUue #LCSM
Thomas Jefferson University Hospital is now enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. Learn more: bit.ly/pre1702-study
October 29, 2025 at 2:00 PM
Thomas Jefferson University Hospital is now enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. Learn more: bit.ly/pre1702-study
Marshfield Clinic is now enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. bit.ly/4hyZUue
Spotlight on Real-World Data Capture: The PrE1702 Registry Study in Lung Cancer
This major new initiative is a unique opportunity for researchers and patients to help build an important real-world data registry of patients with EGFR-mutated non-small cell lung cancer
bit.ly
October 15, 2025 at 4:37 PM
Marshfield Clinic is now enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. bit.ly/4hyZUue
Kudos to the following institutions for enrolling their first patients in #RealWorldData #PatientRegistry PrE1702: Sibley Memorial Hospital, Good Samaritan University Hospital, and Northwestern University! More info here: bit.ly/pre1702-study #LCSM #RWD #RWE
ClinicalTrials.gov
bit.ly
October 7, 2025 at 4:06 PM
Kudos to the following institutions for enrolling their first patients in #RealWorldData #PatientRegistry PrE1702: Sibley Memorial Hospital, Good Samaritan University Hospital, and Northwestern University! More info here: bit.ly/pre1702-study #LCSM #RWD #RWE
Kudos to The Valley Hospital (Luckow Pavilion) for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. bit.ly/4hyZUue
Spotlight on Real-World Data Capture: The PrE1702 Registry Study in Lung Cancer
This major new initiative is a unique opportunity for researchers and patients to help build an important real-world data registry of patients with EGFR-mutated non-small cell lung cancer
bit.ly
September 25, 2025 at 6:28 PM
Kudos to The Valley Hospital (Luckow Pavilion) for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. bit.ly/4hyZUue
Kudos to Aurora Saint Luke’s Medical Center for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. bit.ly/4hyZUue
Spotlight on Real-World Data Capture: The PrE1702 Registry Study in Lung Cancer
This major new initiative is a unique opportunity for researchers and patients to help build an important real-world data registry of patients with EGFR-mutated non-small cell lung cancer
bit.ly
September 10, 2025 at 2:17 PM
Kudos to Aurora Saint Luke’s Medical Center for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. bit.ly/4hyZUue
Kudos to John H. Stroger, Jr. Hospital of Cook County for enrolling their 1st patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in pts not in a #ClinicalTrial. bit.ly/4hyZUue
Spotlight on Real-World Data Capture: The PrE1702 Registry Study in Lung Cancer
This major new initiative is a unique opportunity for researchers and patients to help build an important real-world data registry of patients with EGFR-mutated non-small cell lung cancer
bit.ly
August 29, 2025 at 4:12 PM
Kudos to John H. Stroger, Jr. Hospital of Cook County for enrolling their 1st patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in pts not in a #ClinicalTrial. bit.ly/4hyZUue
University of Wisconsin Carbone Cancer Center is now enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in pts not in a #ClinicalTrial. bit.ly/4hyZUue
Spotlight on Real-World Data Capture: The PrE1702 Registry Study in Lung Cancer
This major new initiative is a unique opportunity for researchers and patients to help build an important real-world data registry of patients with EGFR-mutated non-small cell lung cancer
bit.ly
August 29, 2025 at 4:05 PM
University of Wisconsin Carbone Cancer Center is now enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in pts not in a #ClinicalTrial. bit.ly/4hyZUue
Sibley Memorial Hospital is now enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in pts not in a #ClinicalTrial. bit.ly/4hyZUue
Spotlight on Real-World Data Capture: The PrE1702 Registry Study in Lung Cancer
This major new initiative is a unique opportunity for researchers and patients to help build an important real-world data registry of patients with EGFR-mutated non-small cell lung cancer
bit.ly
August 20, 2025 at 2:25 PM
Sibley Memorial Hospital is now enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in pts not in a #ClinicalTrial. bit.ly/4hyZUue
Kudos to The University of Alabama at Birmingham for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. More: bit.ly/4hyZUue
Spotlight on Real-World Data Capture: The PrE1702 Registry Study in Lung Cancer
This major new initiative is a unique opportunity for researchers and patients to help build an important real-world data registry of patients with EGFR-mutated non-small cell lung cancer
bit.ly
August 19, 2025 at 6:09 PM
Kudos to The University of Alabama at Birmingham for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. More: bit.ly/4hyZUue
Reposted by PrECOG
ICYMI: Check out our round-up of recently published @eaonc.bsky.social and @precogonc.bsky.social research results. More here ➡️ bit.ly/july25research
#ClinicalTrials #BreastCancer #CancerControl #CancerSurvivorship #HeadandNeck #LungCancer #Melanoma
#ClinicalTrials #BreastCancer #CancerControl #CancerSurvivorship #HeadandNeck #LungCancer #Melanoma
August 5, 2025 at 3:10 PM
ICYMI: Check out our round-up of recently published @eaonc.bsky.social and @precogonc.bsky.social research results. More here ➡️ bit.ly/july25research
#ClinicalTrials #BreastCancer #CancerControl #CancerSurvivorship #HeadandNeck #LungCancer #Melanoma
#ClinicalTrials #BreastCancer #CancerControl #CancerSurvivorship #HeadandNeck #LungCancer #Melanoma
Great work to Atlantic Health System for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. More: bit.ly/4hyZUue #LCSM
Spotlight on Real-World Data Capture: The PrE1702 Registry Study in Lung Cancer
This major new initiative is a unique opportunity for researchers and patients to help build an important real-world data registry of patients with EGFR-mutated non-small cell lung cancer
bit.ly
July 28, 2025 at 3:30 PM
Great work to Atlantic Health System for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. More: bit.ly/4hyZUue #LCSM
Kudos to The Cancer Institute at Saint Francis Hospital for enrolling their 1st patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in pts not in a #ClinicalTrial. bit.ly/4hyZUue
Spotlight on Real-World Data Capture: The PrE1702 Registry Study in Lung Cancer
This major new initiative is a unique opportunity for researchers and patients to help build an important real-world data registry of patients with EGFR-mutated non-small cell lung cancer
bit.ly
July 8, 2025 at 4:17 PM
Kudos to The Cancer Institute at Saint Francis Hospital for enrolling their 1st patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in pts not in a #ClinicalTrial. bit.ly/4hyZUue